Site Sponsors
  • Park Systems - Manufacturer of a complete range of AFM solutions
  • Strem Chemicals - Nanomaterials for R&D
  • Oxford Instruments Nanoanalysis - X-Max Large Area Analytical EDS SDD
Posted in | Nanomedicine | Nanobusiness

Researchers Gain Access to Sigma-Aldrich's Leading MISSION shRNA Libraries

Published on October 15, 2008 at 4:01 PM

Sigma-Aldrich, a leading life science company and member of The RNAi Consortium (TRC), proudly welcomes the Memorial Sloan-Kettering Cancer Center to the RNAi Partnership Program. The RNAi Partnership Program provides new members with access to cutting-edge products in Sigma-Aldrich's functional genomics portfolio, including shRNA libraries developed by TRC targeting more than 15,000 human genes and 15,000 mouse genes.

"We are excited to become a member of the RNAi Partnership Program and we look forward to productive collaborations with our colleagues at Sigma- Aldrich," said Dr. Hakim Djaballah, Director of the High Throughput Screening Core Facility. "Many of our researchers are interested in targeted gene knockdown on an individual or gene-focused basis, as well as a genome-wide scale for which we are fully equipped. Access to Sigma-Aldrich's MISSION shRNA libraries will greatly enhance our current gene scanning capabilities and will enable us to discover and validate cancer-causing genes and pathways which will hopefully lead to novel approaches to therapeutic intervention for cancer patients."

Through the RNAi Partnership Program, Sigma-Aldrich aims to establish collaborations with select academic institutions. The company advances functional genomics research by aiding academic researchers with early exposure to emerging new techniques, a broad portfolio of intellectual property, and special partnership pricing on Sigma-Aldrich's extensive RNAi product lines. Existing members of the RNAi Partnership Program include The Cleveland Clinic, The Harvard Stem Cell Institute, Washington University of St. Louis, Princeton University, The Wistar Institute, and Rutgers University. These members enjoy unique access to cutting-edge RNAi tools for the study of basic gene function and the underlying causes of disease.

"Sigma-Aldrich is committed to expanding our collaborative relationships with prestigious institutions like the Memorial-Sloan Kettering Cancer Center," said Tim Fleming, Sigma-Aldrich's Director of Global Commercial Marketing for Life Sciences. "We look forward to the success of the Memorial Sloan-Kettering researchers utilizing our leading MISSION library, and will continue to look for innovative ways to accelerate our partners' success."

Sigma-Aldrich has recently made major commitments to the rapidly developing area of RNAi. This began with the establishment of research collaborations with the RNAi Consortium, followed by licensing agreements with MIT to make and sell the shRNA libraries developed by TRC and, subsequently, the introduction of Sigma-Aldrich's MISSION TRC shRNA libraries. Additional agreements with Alnylam, Benitec and Oxford BioMedica provide Sigma-Aldrich with a major intellectual property portfolio in RNAi.

For more information about The RNAi Consortium and participating members, please visit http://www.broad.mit.edu/rnai/trc.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Submit